157 related articles for article (PubMed ID: 10194556)
1. Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors.
Sava G; Clerici K; Capozzi I; Cocchietto M; Gagliardi R; Alessio E; Mestroni G; Perbellini A
Anticancer Drugs; 1999 Jan; 10(1):129-38. PubMed ID: 10194556
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex.
Sava G; Capozzi I; Clerici K; Gagliardi G; Alessio E; Mestroni G
Clin Exp Metastasis; 1998 May; 16(4):371-9. PubMed ID: 9626816
[TBL] [Abstract][Full Text] [Related]
3. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
Bergamo A; Gagliardi R; Scarcia V; Furlani A; Alessio E; Mestroni G; Sava G
J Pharmacol Exp Ther; 1999 Apr; 289(1):559-64. PubMed ID: 10087050
[TBL] [Abstract][Full Text] [Related]
4. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice.
Sava G; Gagliardi R; Cocchietto M; Clerici K; Capozzi I; Marrella M; Alessio E; Mestroni G; Milanino R
Pathol Oncol Res; 1998; 4(1):30-6. PubMed ID: 9555118
[TBL] [Abstract][Full Text] [Related]
6. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
Bergamo A; Gava B; Alessio E; Mestroni G; Serli B; Cocchietto M; Zorzet S; Sava G
Int J Oncol; 2002 Dec; 21(6):1331-8. PubMed ID: 12429985
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
[TBL] [Abstract][Full Text] [Related]
8. Effects of the Ru(III) complexes [mer-RuCl3(DMSO)2Im]degrees and Na[trans-RuCl4(DMSO)Im] on solid mouse tumors.
Sava G; Pacor S; Mestroni G; Alessio E
Anticancer Drugs; 1992 Feb; 3(1):25-31. PubMed ID: 1623212
[TBL] [Abstract][Full Text] [Related]
9. Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration.
Cocchietto M; Zorzet S; Sorc A; Sava G
Invest New Drugs; 2003 Feb; 21(1):55-62. PubMed ID: 12795530
[TBL] [Abstract][Full Text] [Related]
10. Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties.
Sava G; Pacor S; Mestroni G; Alessio E
Clin Exp Metastasis; 1992 Jul; 10(4):273-80. PubMed ID: 1617835
[TBL] [Abstract][Full Text] [Related]
11. Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[[trans-RuCl4(Me2SO)]2(mu-L)] (L = ditopic, non-chelating aromatic N-ligand). A preliminary investigation.
Alessio E; Iengo E; Zorzet S; Bergamo A; Coluccia M; Boccarelli A; Sava G
J Inorg Biochem; 2000 Apr; 79(1-4):173-7. PubMed ID: 10830863
[TBL] [Abstract][Full Text] [Related]
12. Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A.
Magnarin M; Bergamo A; Carotenuto ME; Zorzet S; Sava G
Anticancer Res; 2000; 20(5A):2939-44. PubMed ID: 11062704
[TBL] [Abstract][Full Text] [Related]
13. Treatment of residual metastases with Na[trans-RuCl4 (DMSO)lm] and ruthenium uptake by tumor cells.
Bergamo A; Cocchietto M; Capozzi I; Mestroni G; Alessio E; Sava G
Anticancer Drugs; 1996 Aug; 7(6):697-702. PubMed ID: 8913439
[TBL] [Abstract][Full Text] [Related]
14. Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse.
Gagliardi R; Sava G; Pacor S; Mestroni G; Alessio E
Clin Exp Metastasis; 1994 Mar; 12(2):93-100. PubMed ID: 8306532
[TBL] [Abstract][Full Text] [Related]
15. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.
Sava G; Bergamo A; Zorzet S; Gava B; Casarsa C; Cocchietto M; Furlani A; Scarcia V; Serli B; Iengo E; Alessio E; Mestroni G
Eur J Cancer; 2002 Feb; 38(3):427-35. PubMed ID: 11818210
[TBL] [Abstract][Full Text] [Related]
16. Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.
Bergamo A; Stocco G; Casarsa C; Cocchietto M; Alessio E; Serli B; Zorzet S; Sava G
Int J Oncol; 2004 Feb; 24(2):373-9. PubMed ID: 14719114
[TBL] [Abstract][Full Text] [Related]
17. Isolation of a murine metastatic cell line and preliminary test of sensitivity to the anti-metastasis agent NAMI-A.
Pacor S; Vadori M; Vita F; Bacac M; Soranzo MR; Zabucchi G; Sava G
Anticancer Res; 2001; 21(4A):2523-30. PubMed ID: 11724317
[TBL] [Abstract][Full Text] [Related]
18. Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulfoxide-ruthenium compounds and cisplatin detected by flow cytometry.
Capozzi I; Clerici K; Cocchietto M; Salerno G; Bergamo A; Sava G
Chem Biol Interact; 1998 May; 113(1):51-64. PubMed ID: 9630847
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral NAMI-A treatment triggers metastasis reduction, which correlates to CD44 regulation and tumor infiltrating lymphocyte recruitment.
Pacor S; Zorzet S; Cocchietto M; Bacac M; Vadori M; Turrin C; Gava B; Castellarin A; Sava G
J Pharmacol Exp Ther; 2004 Aug; 310(2):737-44. PubMed ID: 15075381
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.
Gava B; Zorzet S; Spessotto P; Cocchietto M; Sava G
J Pharmacol Exp Ther; 2006 Apr; 317(1):284-91. PubMed ID: 16368900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
